NCT06833112View on ClinicalTrials.gov

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

February 29, 2028

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Secukinumab

The subjects were treated with secukinumab for 104 weeks. Secukinumab:150mg，q8w，subcutaneous injection.

DRUG

Adalimumab

The subjects were treated with adalimumab for 104 weeks. adalimumab: 40mg，q4w，subcutaneous injection.

Trial Locations (1)

550002

The Affiliated Hospital of Guizhou Medical University, Guiyang

All Listed Sponsors
lead

The Affiliated Hospital Of Guizhou Medical University

OTHER